Anavex Life Sciences (AVXL) Enterprise Value Growth (3y) (2013 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.84% |
| Sep 30, 2025 | 11.73% |
| Jun 30, 2025 | 12.92% |
| Mar 31, 2025 | 8.94% |
| Dec 31, 2024 | 7.20% |
| Sep 30, 2024 | 4.57% |
| Jun 30, 2024 | 4.15% |
| Mar 31, 2024 | -22.48% |
| Dec 31, 2023 | -44.80% |
| Sep 30, 2023 | -72.84% |
| Jun 30, 2023 | -77.64% |
| Mar 31, 2023 | -79.44% |
| Dec 31, 2022 | -73.59% |
| Sep 30, 2022 | -88.74% |
| Jun 30, 2022 | -93.14% |
| Mar 31, 2022 | -98.95% |
| Dec 31, 2021 | -93.82% |
| Sep 30, 2021 | -87.89% |
| Jun 30, 2021 | -82.72% |
| Mar 31, 2021 | -43.53% |
| Dec 31, 2020 | -19.08% |
| Sep 30, 2020 | -2.15% |
| Jun 30, 2020 | -3.66% |
| Mar 31, 2020 | -4.39% |
| Dec 31, 2019 | -9.07% |
| Sep 30, 2019 | -34.16% |
| Jun 30, 2019 | -29.78% |
| Sep 30, 2018 | -14.46% |
| Jun 30, 2018 | -48.04% |
| Mar 31, 2018 | -59.60% |
| Dec 31, 2017 | -58.98% |
| Sep 30, 2017 | -55.75% |
| Jun 30, 2017 | -44.72% |
| Mar 31, 2017 | -36.44% |
| Dec 31, 2016 | -504.23% |
| Sep 30, 2016 | -198.60% |
| Jun 30, 2016 | -1,708.30% |
| Sep 30, 2015 | -1,004.06% |
| Jun 30, 2015 | -659.18% |
| Mar 31, 2015 | -228.11% |
| Dec 31, 2014 | -816.13% |
| Sep 30, 2014 | -277.77% |
| Jun 30, 2014 | -88.43% |
| Mar 31, 2014 | -1,261.72% |
| Sep 30, 2013 | -9.25% |